|
|
|
LifeScienceHistory.com - Check us out on Instagram
Massachusetts Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MassachusettsLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
bluebird bio, Inc.
| | | Phone: | (617) 491-5601 | Fax: | (617) 576-2421 | Year Established: | 1998 | Ticker: | BLUE | Exchange: | NASDAQ | Main Contact: | Alison Finger, CCO | | Other Contacts: | Joanne Smith-Farrell, Ph.D., Senior VP, Corporate Development & Strategy Jason F. Cole, Esq., CLO Derek Adams, Ph.D., Chief Technology & Manufacturing Officer Andrew Obenshain, Senior VP & Head of Europe Mark D. Angelino, Ph.D., Senior VP, Pharmaceutical Sciences Jeffrey Walsh, CFO & Strategy Officer David M. Davidson, M.D., CMO Susanna High, COO Nick Leschly, President & CEO Philip Gregory, D. Phil., CSO
| | Company Description | bluebird bio (formerly Genetix Pharmaceuticals) is developing innovative gene therapies for severe genetic disorders. At the heart of bluebird bio’s product creation efforts is its broadly applicable gene therapy platform for the development of novel treatments for diseases with few or no clinical options. The company’s novel approach uses stem cells harvested from the patient’s own bone marrow into which a healthy version of the disease causing gene is inserted. bluebird bio’s approach represents a true paradigm shift in the treatment of severe genetic diseases by eliminating the potential
complications associated with donor cell transplantation and potentially presenting a one-time transformative therapy using a patient’s own stem cells. bluebird bio has two later stage clinical products in development for childhood cerebral adrenoleukodystrophy (CCALD) and betathalassemia, and plans to initiate a program in sickle cell disease. Led by a world-class team, its operations are located in Cambridge, Mass. and Paris, France. | |
|
|
|
|
|